$GRTX
Galera Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022015753 Filed on August 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.853M $5.293M $5.047M
YoY Change -11.55% 3.34% -0.26%
% of Gross Profit
Research & Development $8.106M $6.662M $8.107M
YoY Change -45.28% -58.27% -34.74%
% of Gross Profit
Depreciation & Amortization $27.00K $30.00K $31.00K
YoY Change -74.53% -69.39% -69.0%
% of Gross Profit
Operating Expenses $8.106M $6.662M $8.107M
YoY Change -45.28% -58.27% -34.74%
Operating Profit -$12.96M -$11.96M -$13.15M
YoY Change -36.16% -43.31% -24.75%
Interest Expense $3.245M $2.699M $2.303M
YoY Change 39.45% 107.3% 83.8%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$16.03M -$14.56M -$15.44M
YoY Change -29.14% -34.97% -17.51%
Income Tax
% Of Pretax Income
Net Earnings -$16.03M -$14.56M -$15.44M
YoY Change -29.14% -34.97% -17.48%
Net Earnings / Revenue
Basic Earnings Per Share -$0.60 -$0.54 -$0.58
Diluted Earnings Per Share -$0.60 -$0.54 -$577.3K
COMMON SHARES
Basic Shares Outstanding 26.82M 26.82M 26.80M
Diluted Shares Outstanding 26.82M 26.82M 26.75M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.77M $52.01M $60.95M
YoY Change -51.79% -21.83% 5.99%
Cash & Equivalents $12.73M $17.38M $19.65M
Short-Term Investments $30.04M $34.63M $41.30M
Other Short-Term Assets $2.148M $3.181M $4.329M
YoY Change -46.07% -34.24% -35.39%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $44.92M $55.19M $65.28M
YoY Change -51.54% -49.31% 1.68%
LONG-TERM ASSETS
Property, Plant & Equipment $464.0K $486.0K $509.0K
YoY Change -50.53% -52.35% -53.89%
Goodwill $881.0K $881.0K $881.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.087M $2.097M $1.946M
YoY Change 28.35% 16.76% 29.73%
Total Long-Term Assets $5.796M $5.890M $5.823M
YoY Change -4.62% -8.04% -7.57%
TOTAL ASSETS
Total Short-Term Assets $44.92M $55.19M $65.28M
Total Long-Term Assets $5.796M $5.890M $5.823M
Total Assets $50.71M $61.08M $71.10M
YoY Change -48.65% -47.01% 0.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.591M $3.588M $4.131M
YoY Change -49.99% -56.62% -55.1%
Accrued Expenses $7.932M $7.226M $6.566M
YoY Change -4.11% -12.8% 3.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.63M $10.99M $10.93M
YoY Change -26.02% -34.77% -31.25%
LONG-TERM LIABILITIES
Long-Term Debt $136.3M $133.1M $130.4M
YoY Change 8.4% 7.81% 101.8%
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Total Long-Term Liabilities $136.3M $133.1M $130.4M
YoY Change 8.24% 7.6% 100.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.63M $10.99M $10.93M
Total Long-Term Liabilities $136.3M $133.1M $130.4M
Total Liabilities $148.2M $144.3M $141.6M
YoY Change 4.43% 2.51% 74.56%
SHAREHOLDERS EQUITY
Retained Earnings -$362.1M -$346.1M -$331.5M
YoY Change 20.98% 25.08% 30.36%
Common Stock $264.7M $263.0M $261.1M
YoY Change 3.36% 4.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$97.50M -$83.25M -$70.47M
YoY Change
Total Liabilities & Shareholders Equity $50.71M $61.08M $71.10M
YoY Change -48.65% -47.01% 0.85%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$16.03M -$14.56M -$15.44M
YoY Change -29.14% -34.97% -17.48%
Depreciation, Depletion And Amortization $27.00K $30.00K $31.00K
YoY Change -74.53% -69.39% -69.0%
Cash From Operating Activities -$9.210M -$8.886M -$11.39M
YoY Change -49.96% -47.13% -25.6%
INVESTING ACTIVITIES
Capital Expenditures -$5.000K -$7.000K $13.00K
YoY Change -80.0% -53.33% -93.01%
Acquisitions
YoY Change
Other Investing Activities $4.609M $6.622M $10.01M
YoY Change -110.71% -57.99% -23.42%
Cash From Investing Activities $4.604M $6.615M $9.996M
YoY Change -110.7% -57.99% -22.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 2.000K 1.175M
YoY Change -99.98% -99.99% 400.0%
NET CHANGE
Cash From Operating Activities -9.210M -8.886M -11.39M
Cash From Investing Activities 4.604M 6.615M 9.996M
Cash From Financing Activities 10.00K 2.000K 1.175M
Net Change In Cash -4.596M -2.269M -214.0K
YoY Change -77.94% -109.16% -90.21%
FREE CASH FLOW
Cash From Operating Activities -$9.210M -$8.886M -$11.39M
Capital Expenditures -$5.000K -$7.000K $13.00K
Free Cash Flow -$9.205M -$8.879M -$11.40M
YoY Change -49.92% -47.13% -26.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001563577
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39114
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Registrant Name
EntityRegistrantName
Galera Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1454898
dei Entity Address Address Line1
EntityAddressAddressLine1
2 W. Liberty Blvd #100
dei Entity Address City Or Town
EntityAddressCityOrTown
Malvern
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
dei City Area Code
CityAreaCode
610
dei Local Phone Number
LocalPhoneNumber
725-1500
dei Security12b Title
Security12bTitle
Common Stock,$0.001 par value per share
dei Trading Symbol
TradingSymbol
GRTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26821589
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17376000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19859000
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
34631000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
51358000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3181000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6175000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
55188000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
77392000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
486000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
527000
CY2022Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2258000
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2258000
CY2022Q2 us-gaap Goodwill
Goodwill
881000
CY2021Q4 us-gaap Goodwill
Goodwill
881000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
168000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
296000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2097000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1957000
CY2022Q2 us-gaap Assets
Assets
61078000
CY2021Q4 us-gaap Assets
Assets
83311000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3588000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5044000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7226000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7633000
CY2022Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
172000
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
258000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10986000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12935000
CY2022Q2 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
133065000
CY2021Q4 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
128063000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44000
CY2022Q2 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
273000
CY2021Q4 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
273000
CY2022Q2 us-gaap Liabilities
Liabilities
144324000
CY2021Q4 us-gaap Liabilities
Liabilities
141315000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26821589
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26821589
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26458767
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26458767
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
27000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
26000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
262940000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
258086000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-110000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-346103000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-316102000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-83246000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-58004000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61078000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83311000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6662000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15966000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14769000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28389000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5293000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5122000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10340000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10180000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11955000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21088000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25109000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38569000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41110000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-58004000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1848000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
71000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
6000
us-gaap Investment Income Interest
InvestmentIncomeInterest
85000
us-gaap Investment Income Interest
InvestmentIncomeInterest
25000
CY2022Q2 us-gaap Interest Expense
InterestExpense
2699000
CY2021Q2 us-gaap Interest Expense
InterestExpense
1302000
us-gaap Interest Expense
InterestExpense
5002000
us-gaap Interest Expense
InterestExpense
2555000
CY2022Q2 grtx Gain On Disposal Of Assets
GainOnDisposalOfAssets
26000
CY2021Q2 grtx Gain On Disposal Of Assets
GainOnDisposalOfAssets
0
grtx Gain On Disposal Of Assets
GainOnDisposalOfAssets
26000
grtx Gain On Disposal Of Assets
GainOnDisposalOfAssets
0
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14558000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22386000
us-gaap Net Income Loss
NetIncomeLoss
-30001000
us-gaap Net Income Loss
NetIncomeLoss
-41101000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.63
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26821303
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26821303
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25401046
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25401046
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26785540
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26785540
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25195763
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25195763
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14558000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22386000
us-gaap Net Income Loss
NetIncomeLoss
-30001000
us-gaap Net Income Loss
NetIncomeLoss
-41101000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-49000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-96000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14607000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22393000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30097000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58000
CY2022Q1 grtx Sale Of Shares Under Open Market Sale Agrrement
SaleOfSharesUnderOpenMarketSaleAgrrement
-1117000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28628000
grtx Proceeds From Royalty Purchase Agreement
ProceedsFromRoyaltyPurchaseAgreement
0
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-47000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15443000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-70471000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1830000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-49000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14558000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-83246000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
6118000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1791000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
235000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18715000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-10573000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1611000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
120000
CY2021Q2 grtx Sale Of Shares Under Open Market Sale Agrrement
SaleOfSharesUnderOpenMarketSaleAgrrement
-5718000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22386000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-25517000
us-gaap Profit Loss
ProfitLoss
-30001000
us-gaap Profit Loss
ProfitLoss
-41101000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
61000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
208000
us-gaap Paid In Kind Interest
PaidInKindInterest
5002000
us-gaap Paid In Kind Interest
PaidInKindInterest
2555000
us-gaap Share Based Compensation
ShareBasedCompensation
3678000
us-gaap Share Based Compensation
ShareBasedCompensation
3402000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2994000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-316000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
12000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
240000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1456000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3126000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-407000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-374000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
130000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20271000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32108000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
34529000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
7167000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
51160000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
36000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
205000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16611000
grtx Proceeds From Royalty Purchase Agreement
ProceedsFromRoyaltyPurchaseAgreement
20000000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
1117000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5718000
grtx Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
98000
CY2021Q2 grtx Operating Lease Interest Expense
OperatingLeaseInterestExpense
6000
grtx Operating Lease Interest Expense
OperatingLeaseInterestExpense
6000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
81000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
60000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
355000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1177000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26073000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2483000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22593000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19859000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15872000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17376000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38465000
grtx Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-11-19
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-346100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited interim consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary. Significant areas that require management’s estimates include share-based compensation assumptions, royalty purchase liability assumptions and accrued research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
grtx Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
300000
grtx Funding Available Under The Grant
FundingAvailableUnderTheGrant
1100000
us-gaap Operating Lease Cost
OperatingLeaseCost
136000
us-gaap Operating Lease Cost
OperatingLeaseCost
162000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5814022
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.01
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6364683
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5560658
us-gaap Fair Value Liabilities Measured On Recurring Basis Debt Instrument Valuation Techniques Change In Technique Quantification Of Effect
FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect
0
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2134000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2114000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1648000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1587000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
486000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
527000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1498000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2038000
CY2022Q2 grtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5264000
CY2021Q4 grtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5360000
CY2022Q2 grtx Accrued Professional Fees And Other Expenses Current
AccruedProfessionalFeesAndOtherExpensesCurrent
464000
CY2021Q4 grtx Accrued Professional Fees And Other Expenses Current
AccruedProfessionalFeesAndOtherExpensesCurrent
235000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7226000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7633000
CY2022Q2 grtx Operating Lease Interest Expense
OperatingLeaseInterestExpense
3000
grtx Operating Lease Interest Expense
OperatingLeaseInterestExpense
13000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
65000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3113199
CY2022Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P6Y
CY2022Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
4700000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
168000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
296000
CY2022Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
172000
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
258000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
172000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
302000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
62000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
75000
us-gaap Operating Lease Expense
OperatingLeaseExpense
130000
us-gaap Operating Lease Expense
OperatingLeaseExpense
149000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5814022
us-gaap Operating Lease Payments
OperatingLeasePayments
135000
us-gaap Operating Lease Payments
OperatingLeasePayments
162000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
70000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
131000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
44000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
175000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
172000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1830000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1611000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3678000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3402000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4970975
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.45
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1356400
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.19
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
48526
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
464827
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.96
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.01
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
13400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.914
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.910
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0186
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0067
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0

Files In Submission

Name View Source Status
0000950170-22-015753-index-headers.html Edgar Link pending
0000950170-22-015753-index.html Edgar Link pending
0000950170-22-015753.txt Edgar Link pending
0000950170-22-015753-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
grtx-20220630.htm Edgar Link pending
grtx-20220630.xsd Edgar Link pending
grtx-20220630_cal.xml Edgar Link unprocessable
grtx-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
grtx-20220630_lab.xml Edgar Link unprocessable
grtx-20220630_htm.xml Edgar Link completed
grtx-ex10_1.htm Edgar Link pending
grtx-ex31_1.htm Edgar Link pending
grtx-ex31_2.htm Edgar Link pending
grtx-ex32_1.htm Edgar Link pending
grtx-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
grtx-20220630_pre.xml Edgar Link unprocessable